AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum [Yahoo! Finance]
Axogen, Inc. (AXGN)
Last axogen, inc. earnings: 2/24 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.axogeninc.com
Company Research
Source: Yahoo! Finance
ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected adoption. BLA label seen as broad, consistent with prior use CEO Mike Dale said the FDA-approved label allows AxoGen to continue the work it was already doing and does not limit use by nerve type. He said there is “no diminution” of the company's ability to serve sensory, motor, and mixed nerves, and that the label is “agnostic” to application, describing the product as “safe and effective” for the treatment of nerve discontinuities. ? Microsoft Positioned to Win AI Race With Dual-Model Strategy Dale added that the BLA approval provides a regulatory foundation that supports continued market development and efforts to establish nerve care as a standard of care consistent with the label. Exclusivity and competitive barriers In discussing exclusivity, management said it understands the BLA positions the pr
Show less
Read more
Impact Snapshot
Event Time:
AXGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AXGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AXGN alerts
High impacting Axogen, Inc. news events
Weekly update
A roundup of the hottest topics
AXGN
News
- AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference [Yahoo! Finance]Yahoo! Finance
- AxoGen, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- A Look At Axogen (AXGN) Valuation After Recent Share Price Pullback And BLA Expectations [Yahoo! Finance]Yahoo! Finance
- Axogen (AXGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position [Seeking Alpha]Seeking Alpha
AXGN
Earnings
- 2/24/26 - Beat
AXGN
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- AXGN's page on the SEC website